Moffitt Researchers Uncover New Prostate Cancer Treatment Approach

Got story updates? Submit your updates here. ›

Researchers at Moffitt Cancer Center have made a significant advancement in understanding and potentially overcoming treatment resistance in prostate cancer. A novel study reveals that prostate cancer cells, when they develop resistance to DNA-damaging treatments like radiation, expose a vulnerability that can be exploited therapeutically. This finding offers a promising new avenue for improving outcomes for patients facing this challenging disease.

Why it matters

Prostate cancer remains a leading cause of cancer-related deaths among men, and a major hurdle in treatment is the development of resistance to standard therapies. This research focuses on the underlying mechanisms driving this resistance, specifically examining the role of the DNA damage response (DDR). Understanding how cancer cells adapt and become resistant to treatments like radiation is crucial for developing more effective and personalized therapies.

The details

The study, building on years of research into the DDR, highlights how alterations in DDR pathways can both contribute to prostate cancer development and affect its progression. Approximately 20% of prostate cancer patients exhibit alterations in these pathways, which can actually enhance their sensitivity to PARP inhibitors, a class of drugs designed to exploit DNA repair deficiencies. The researchers found that when prostate cancer cells become resistant to radiation, they don't simply shut down the DDR, but rather alter it, creating a new set of vulnerabilities that can be targeted with specific therapies.

• The study was published in December 2023.
• The FDA approved two PARP inhibitors, olaparib and rucaparib, for prostate cancer treatment in May 2020.

What’s next

Clinical trials are underway to evaluate the efficacy of new strategies targeting the DNA damage response in patients with advanced prostate cancer.